topotecan has been researched along with Weight Loss in 6 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (66.67) | 29.6817 |
| 2010's | 2 (33.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Doles, JD; Hogan, KA; Huston, O; Jatoi, A; O'Connor, J; Wahner Hendrickson, AE | 1 |
| Balthasar, JP; Shah, DK | 1 |
| Agata, N; Bagley, RG; Battle, T; Crawford, J; Ewesuedo, R; Krumbholz, R; Kurtzberg, LS; Lavoie, EJ; Roth, S; Rouleau, C; Schmid, S; Teicher, BA; Wang, F; Yao, M; Yu, XJ | 1 |
| Balsari, A; Besusso, D; Maggi, R; Ménard, S; Petrangolini, G; Pratesi, G; Sfondrini, L; Tortoreto, M | 1 |
| Bugat, R; Canal, P; Chatelut, E; Guichard, S; Hennebelle, I; Montazeri, A | 1 |
| Chen, BM; Chern, JW; Leu, YL; Prijovich, ZM; Roffler, SR | 1 |
6 other study(ies) available for topotecan and Weight Loss
| Article | Year |
|---|---|
Does the Poly (ADP-Ribose) Polymerase Inhibitor Veliparib Merit Further Study for Cancer-Associated Weight Loss? Observations and Conclusions from Sixty Prospectively Treated Patients.
Topics: Adult; Aged; Benzimidazoles; Cachexia; Female; Humans; Male; Middle Aged; Neoplasms; Poly(ADP-ribose) Polymerase Inhibitors; Prospective Studies; Tomography, X-Ray Computed; Topoisomerase Inhibitors; Topotecan; Weight Loss | 2018 |
PK/TD modeling for prediction of the effects of 8C2, an anti-topotecan mAb, on topotecan-induced toxicity in mice.
Topics: Animals; Antibodies, Monoclonal; Computer Simulation; Dose-Response Relationship, Drug; Enzyme-Linked Immunosorbent Assay; Injections, Intravenous; Injections, Subcutaneous; Male; Mice; Models, Biological; Nonlinear Dynamics; Risk Assessment; Topoisomerase I Inhibitors; Topotecan; Weight Loss | 2014 |
Bone marrow and tumor cell colony-forming units and human tumor xenograft efficacy of noncamptothecin and camptothecin topoisomerase I inhibitors.
Topics: Animals; Antineoplastic Agents; Body Weight; Bone Marrow; Camptothecin; Cell Line, Tumor; Cell Proliferation; Confidence Intervals; Dose-Response Relationship, Drug; Flow Cytometry; Humans; Inhibitory Concentration 50; Irinotecan; Male; Mice; Mice, Inbred BALB C; Naphthyridines; Neoplastic Stem Cells; Topoisomerase I Inhibitors; Topotecan; Weight Loss; Xenograft Model Antitumor Assays | 2008 |
Combination of a CpG-oligodeoxynucleotide and a topoisomerase I inhibitor in the therapy of human tumour xenografts.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Humans; Interferon-gamma; Interleukin-12; Male; Maximum Tolerated Dose; Mice; Mice, Nude; Neoplasm Transplantation; Oligodeoxyribonucleotides; Prostatic Neoplasms; Topotecan; Transplantation, Heterologous; Weight Loss | 2004 |
Schedule-dependent activity of topotecan in OVCAR-3 ovarian carcinoma xenograft: pharmacokinetic and pharmacodynamic evaluation.
Topics: Animals; Antineoplastic Agents; DNA Topoisomerases, Type I; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Mice; Mice, Nude; Ovarian Neoplasms; Time Factors; Topoisomerase I Inhibitors; Topotecan; Treatment Outcome; Tumor Cells, Cultured; Weight Loss; Xenograft Model Antitumor Assays | 2001 |
Anti-tumour activity and toxicity of the new prodrug 9-aminocamptothecin glucuronide (9ACG) in mice.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Breast Neoplasms; Camptothecin; Drug Stability; Female; Glucuronides; Humans; Lung Neoplasms; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Ovarian Neoplasms; Prodrugs; Sex Factors; Solubility; Topotecan; Tumor Cells, Cultured; Weight Loss; Xenograft Model Antitumor Assays | 2002 |